Zacks: Brokerages Anticipate Ascendis Pharma A/S (NASDAQ:ASND) Will Announce Quarterly Sales of $2.26 Million

Share on StockTwits

Wall Street analysts expect that Ascendis Pharma A/S (NASDAQ:ASND) will report sales of $2.26 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings, with the lowest sales estimate coming in at $1.52 million and the highest estimate coming in at $2.77 million. Ascendis Pharma A/S posted sales of $12.00 million in the same quarter last year, which would indicate a negative year over year growth rate of 81.2%. The company is expected to announce its next quarterly earnings report on Wednesday, April 1st.

On average, analysts expect that Ascendis Pharma A/S will report full year sales of $13.71 million for the current fiscal year, with estimates ranging from $12.08 million to $15.07 million. For the next year, analysts anticipate that the company will post sales of $6.56 million, with estimates ranging from $1.12 million to $13.80 million. Zacks’ sales averages are an average based on a survey of research firms that cover Ascendis Pharma A/S.

Several equities analysts have recently issued reports on the company. Leerink Swann reiterated an “outperform” rating and issued a $152.00 price objective (up previously from $140.00) on shares of Ascendis Pharma A/S in a research note on Tuesday. ValuEngine cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Tuesday. Morgan Stanley assumed coverage on Ascendis Pharma A/S in a research note on Friday, October 11th. They issued an “overweight” rating and a $128.00 price objective for the company. Wedbush reiterated a “buy” rating and issued a $186.00 price objective on shares of Ascendis Pharma A/S in a research note on Tuesday, November 19th. Finally, BidaskClub cut Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Ascendis Pharma A/S has a consensus rating of “Buy” and an average target price of $150.50.

Shares of ASND traded up $2.49 during midday trading on Friday, hitting $116.24. The company had a trading volume of 144,737 shares, compared to its average volume of 299,879. The company’s 50-day simple moving average is $109.71 and its 200-day simple moving average is $112.61. The company has a debt-to-equity ratio of 0.05, a quick ratio of 15.75 and a current ratio of 15.74. The firm has a market capitalization of $4.85 billion, a P/E ratio of -31.08 and a beta of 0.63. Ascendis Pharma A/S has a 1 year low of $54.67 and a 1 year high of $133.96.

Hedge funds have recently bought and sold shares of the stock. Voloridge Investment Management LLC increased its stake in Ascendis Pharma A/S by 1,076.9% during the third quarter. Voloridge Investment Management LLC now owns 24,361 shares of the biotechnology company’s stock worth $2,346,000 after acquiring an additional 22,291 shares during the last quarter. Castleark Management LLC increased its stake in Ascendis Pharma A/S by 15.4% during the third quarter. Castleark Management LLC now owns 4,730 shares of the biotechnology company’s stock worth $456,000 after acquiring an additional 630 shares during the last quarter. Barclays PLC increased its stake in Ascendis Pharma A/S by 2,789.6% during the third quarter. Barclays PLC now owns 8,611 shares of the biotechnology company’s stock worth $829,000 after acquiring an additional 8,313 shares during the last quarter. Stifel Financial Corp increased its stake in Ascendis Pharma A/S by 62.5% during the third quarter. Stifel Financial Corp now owns 4,203 shares of the biotechnology company’s stock worth $407,000 after acquiring an additional 1,616 shares during the last quarter. Finally, State Street Corp increased its stake in Ascendis Pharma A/S by 3.9% during the third quarter. State Street Corp now owns 9,352 shares of the biotechnology company’s stock worth $901,000 after acquiring an additional 352 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: What is quantitative easing?

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.